Metabolic Stack
Single-Agonist To Triple-Agonist, Side By Side
The reference pair for incretin-pathway research — a pure GLP-1 agonist (Semaglutide) alongside the triple-agonist Retatrutide. Lets investigators bracket single-receptor versus poly-agonist response in one protocol.
The incretin research literature shifted between 2022 and 2025 from single-receptor GLP-1 work to dual and triple agonist comparisons. Labs running adipose tissue, hepatic insulin sensitivity, or food-intake models now routinely benchmark against both a known single-receptor reference (Semaglutide) and a multi-receptor reference (Retatrutide). Sourcing the pair together is the standard way to keep dose-response curves comparable.
Both peptides are synthesized to identical purity targets (≥98% by HPLC), lyophilized in matched 5mg vials, and sealed under inert gas at the Tampa facility. Pair-matched Certificate of Analysis includes mass-spec verification for both molecules referenced against canonical sequences. Labs that previously sourced these from two different vendors report visible variance in dose-response curves — same-lab synthesis removes that variable.
What ships in the box
- Retatrutide 10mg — triple agonist (GLP-1 / GIP / glucagon)
- Semaglutide 5mg — selective GLP-1 receptor agonist
- Matching bacteriostatic water (2× 3 mL)
- Pair-matched HPLC + mass-spec Certificate of Analysis
Best for
Pair price $199 — saves $45 versus separate vials ($248 MSRP). Subscribe & Save 15% off recurring orders and lot-locks both compounds to one synthesis window, holding the reference standard constant across multi-month study arms.